- Home
- DMAC vs ESCA Comparison
DMAC vs ESCA Comparison
Compare DMAC & ESCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- ESCA
- Stock Information
- Founded
- DMAC 2000
- ESCA 1922
- Country
- DMAC United States
- ESCA United States
- Employees
- DMAC N/A
- ESCA N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- ESCA Recreational Games/Products/Toys
- Sector
- DMAC Health Care
- ESCA Consumer Discretionary
- Exchange
- DMAC Nasdaq
- ESCA Nasdaq
- Market Cap
- DMAC 178.0M
- ESCA 209.5M
- IPO Year
- DMAC N/A
- ESCA N/A
- Fundamental
- Price
- DMAC $3.76
- ESCA $14.98
- Analyst Decision
- DMAC Strong Buy
- ESCA
- Analyst Count
- DMAC 2
- ESCA 0
- Target Price
- DMAC $8.00
- ESCA N/A
- AVG Volume (30 Days)
- DMAC 307.4K
- ESCA 20.5K
- Earning Date
- DMAC 08-06-2025
- ESCA 07-24-2025
- Dividend Yield
- DMAC N/A
- ESCA 4.01%
- EPS Growth
- DMAC N/A
- ESCA 9.37
- EPS
- DMAC N/A
- ESCA 0.99
- Revenue
- DMAC N/A
- ESCA $249,685,000.00
- Revenue This Year
- DMAC N/A
- ESCA N/A
- Revenue Next Year
- DMAC N/A
- ESCA N/A
- P/E Ratio
- DMAC N/A
- ESCA $15.14
- Revenue Growth
- DMAC N/A
- ESCA N/A
- 52 Week Low
- DMAC $2.80
- ESCA $12.54
- 52 Week High
- DMAC $6.82
- ESCA $16.99
- Technical
- Relative Strength Index (RSI)
- DMAC 47.18
- ESCA 58.48
- Support Level
- DMAC $3.48
- ESCA $13.84
- Resistance Level
- DMAC $3.99
- ESCA $15.00
- Average True Range (ATR)
- DMAC 0.32
- ESCA 0.57
- MACD
- DMAC -0.00
- ESCA 0.11
- Stochastic Oscillator
- DMAC 41.01
- ESCA 98.88
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About ESCA Escalade Incorporated
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.